BioNTech SE (BNTX)
NASDAQ: BNTX · Real-Time Price · USD
114.83
+10.15 (9.70%)
Apr 23, 2025, 4:00 PM EDT - Market closed
BioNTech SE Employees
BioNTech SE had 6,772 employees as of December 31, 2024. The number of employees increased by 639 or 10.42% compared to the previous year.
Employees
6,772
Change (1Y)
639
Growth (1Y)
10.42%
Revenue / Employee
$420,588
Profits / Employee
-$101,711
Market Cap
27.56B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 6,772 | 639 | 10.42% |
Dec 31, 2023 | 6,133 | 1,603 | 35.39% |
Dec 31, 2022 | 4,530 | 1,448 | 46.98% |
Dec 31, 2021 | 3,082 | 1,141 | 58.78% |
Dec 31, 2020 | 1,941 | 631 | 48.17% |
Dec 31, 2019 | 1,310 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novartis AG | 75,883 |
BNTX News
- 2 days ago - BioNTech to Report First Quarter 2025 Financial Results and Corporate Update on May 5, 2025 - GlobeNewsWire
- 23 days ago - Vaccine stocks tumble: Moderna, Novavax, Pfizer fall after top FDA official resigns over RFK Jr. anti-vax views - Fast Company
- 23 days ago - Drug stocks sink as FDA's top vaccine official is ousted in Trump overhaul - New York Post
- 23 days ago - Vaccine stocks fall after key FDA official resigns in protest of RFK Jr. - CNBC
- 24 days ago - Biotech stocks tumble on reports FDA's top vaccine regulator to leave - Reuters
- 26 days ago - CureVac Shares Rise on Patent Confirmation Amid BioNTech Lawsuit - Market Watch
- 4 weeks ago - Refractory Metastatic Melanoma Pipeline Report 2025, with Focus on BioNTech SE, Y-mAbs and Therapeutics Seagen - GlobeNewsWire
- 5 weeks ago - BioNTech's Pivot Into Oncology Still Makes It A Compelling Investment - Seeking Alpha